Israel Says Agreed With AstraZeneca on COVID Vaccine Rations for 5 Million People

Under the agreement, AstraZeneca vaccines would begin arriving in Israel in first half of 2021 ■ Deal includes largest supply of rations Israel has secured so far

Ido Efrati
Noa Landau
Reuters
Send in e-mailSend in e-mail
An AstraZeneca logo.
An AstraZeneca logo.Credit: JUSTIN TALLIS / AFP
Ido Efrati
Noa Landau
Reuters

Israel said Friday it is in advanced stages of negotiations with British drug maker AstraZeneca to secure the supply of a coronavirus vaccine for five million people.

Under to the agreement, AstraZeneca would provide some 10 million vaccine doses, with its vaccine requiring two doses per person. The vaccine would be sold under a nonprofit model – the company would not profit from selling the product to Israel during the pandemic.

Haaretz podcast: Will Trump's purged Pentagon let Israel attack Iran?

Subscribe
0:00
-- : --

The initial supply of AstraZeneca vaccines would arrive in Israel in the first half of 2021 subject to regulatory authorities in Europe, the United States and Israel.

This deal would include the biggest supply of vaccines Israel has secured so far. The talks to seal the deal are held on the order by Prime Minister Benjamin Netanyahu and Health Minister Yuli Edelstein. 

Currently, Israel only has agreements with three drug companies developing coronavirus vaccines: , which has recently said that their new test results show its coronavirus vaccine is 95% effective, , which said its vaccine is 94.5% effective and is now at a late-stage clinical trial , and , which is still in the first stage.

Data published on Thursday showed that AstraZeneca and Oxford University’s potential vaccine produced a strong immune response in older adults, with researchers expecting to release late-stage trial results by Christmas.

The data, reported in part last month but published in full in The Lancet medical journal on Thursday, suggest that those aged over 70, who are at higher risk of serious illness and death from COVID-19, could build robust immunity.

“The robust antibody and T-cell responses seen in older people in our study are encouraging,” said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group.

“We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure.”

Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions.

Results of those trials should definitely be known by Christmas, the Oxford Vaccine Group’s director, Andrew Pollard, said, adding it was too early to know whether and how well the vaccine works in preventing COVID-19 disease.

“We’re still waiting to get to the point where we can do the analysis to just work out how well the vaccine can protect people, and we’re getting ever closer to that,” he told journalists.

“We are optimistic that we’ll be able to do that before Christmas, and obviously we’ll share that with you as soon as we can at that point.”

The Oxford-AstraZeneca COVID-19 vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, had been among the front-runners in global efforts to develop shots to protect against infection with the novel coronavirus, or SARS-CoV-2.

“We’re not in a rush. We and it’s not a competition with the other developers,” Oxford’s Pollard said, adding that AstraZeneca would release headline efficacy data before it was published in an academic journal.

Oxford University has set a target of 53 infections to start the interim analysis of its late-stage trial results, though “lots of cases” in its trial arms in Britain, South Africa and Brazil mean the exact number of infections reported could differ.

Unlike the Pfizer and Moderna shots, both of which use new technology known as messenger RNA (mRNA), AstraZeneca’s is a viral vector vaccine made from a weakened version of a common cold virus found in chimpanzees.

The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55, 160 aged 56-69, and 240 aged 70 or over.

Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world.

Comments